Skip to content

The Effect of Enhanced Recovery After Surgery (ERAS) in Gastric Cancer Surgery

The Effect of Enhanced Recovery After Surgery (ERAS) in Gastric Cancer Surgery

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06209983
Enrollment
38
Registered
2024-01-18
Start date
2018-12-05
Completion date
2027-12-31
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesiology, General Surgery

Keywords

ERAS, Postoperative Complications

Brief summary

The investigators aimed to clarify the clinical relevance of the ERAS protocol by evaluating the perioperative course in patients undergoing laparoscopic gastric cancer surgery.

Detailed description

Gastric cancer is 7th common malignant disease in Taiwan, accounting for 3000 new cases per year. The main treatment of gastric cancer is radical gastrectomy and lymph nodes dissection, which is associated with 13.0\ 46 % of surgical morbidities. To minimize the surgical morbidities and enhance patients' recovery, perioperative management is mandatory. Enhanced Recovery After Surgery (ERAS) is a multimodal, multidisciplinary approach to the care of the surgical patient. ERAS process implementation involves a team consisting of surgeons, anesthetists, an ERAS coordinator, and staff from units that care for the surgical patient. The main elements of ERAS include carbohydrate loading before surgery, minimally invasive approaches, balanced management of intravenous fluids, multimodal pain management, early mobilization, and early oral feeding, etc. Some prospective studies have shown its effectiveness in reduce surgical morbidity and hospital stay in colorectal surgery. In Taiwan, there was only limited report to study the use of ERAS in gastric cancer surgery. The investigators would like to integrate these perioperative interventions into the ERAS program, and test its effectiveness in gastric cancer patients undergoing radical gastrectomy at NTUH.

Interventions

PROCEDUREERAS

1. Preoperative preparation: shorten the fasting time, take a small amount of sugar water two hours before the surgery, and reduce excessive bowel preparation. 2. Intraoperative care: multi-model analgesia (mainly epidural analgesia), sleep depth monitoring, warm air blanket to avoid hypothermia. 3. Postoperative care: focus on pain relief methods (such as oral analgesics, patient-controlled epidural analgesia), early postoperative feeding (try drinking water on the first day after surgery, liquid diet on the second day, and soft diet on the third day), early removal of invasive tubes such as nasogastric tubes, intravenous catheters, and urinary catheters, and medication to prevent postoperative nausea and vomiting.

PROCEDUREConventional care

1. Preoperative preparation: overnight fasting preparation, bowel preparation. 2. Intraoperative care: traditional pain care (intravenous analgesics), sleep depth monitoring, warm air blanket, central venous pressure and body water monitoring indicators, traditional muscle tension relaxation treatment and the use of health insurance antagonist drugs (Neostigmine). 3. Postoperative care: patient-controlled intravenous drip for postoperative pain relief, oral feeing (rice porridge) on the postoperative day 5, and according to the progression of patient condition, step by step to removal of invasive tubes such as nasogastric tubes, intravenous catheters, and urinary catheters.

Sponsors

National Taiwan University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Pathological confirmed as gastric adenocarcinoma; * Gastric cancer patients who will undergo subtotal gastrectomy.

Exclusion criteria

* Advanced gastric cancer with gastric outlet obstruction; * Epidural catheter placement contraindicated or inexecutable; * Have other cancers that have received chemotherapy or radiation therapy; * Coagulation abnormalities; * Pregnancy; * Severe dysfunction of major organs (e.g., heart failure, chronic obstructive pulmonary disease, liver cirrhosis, end-stage renal disease)

Design outcomes

Primary

MeasureTime frameDescription
Length of hospital stayFrom date of admission until the date of discharge, assessed up to 2 weeks.When patient discharge.

Secondary

MeasureTime frameDescription
Complication rates28 daysThe complication rates means if there are any complications occur.

Other

MeasureTime frameDescription
Readmission rateswithin 28 dayswhen the patient is readmitted to the hospital
costs of hospitalizationFrom date of admission until the date of discharge, assessed up to 2 weeks.Total medical expenses incurred during the admission period.

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026